Publication:
Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri-axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance

Simple item page
dc.contributor.authorTATAR, ESRA
dc.contributor.authorGÜNDÜZ, OĞUZHAN
dc.contributor.authorsGuler E., Nur Hazar-Yavuz A., TATAR E., Morid Haidari M., Sinemcan Ozcan G., DURUKSU G., Graça M. P. F., Kalaskar D. M., GÜNDÜZ O., Emin Cam M.
dc.date.accessioned2023-03-03T10:31:13Z
dc.date.available2023-03-03T10:31:13Z
dc.date.issued2023-03-25
dc.description.abstractEmpagliflozin (EM) was successfully loaded in polycaprolactone/poly (L-lactic acid)/polymethyl methacrylate (PCL/PLA/PMMA) fibers. In the rat β-cell line (BRIN-BD11), the insulin expression ratio of pancreatic β-cells was stimulated at high and low glucose by culturing with tri-layer EM-loaded fiber (EMF) for 48 h. The expression ratios of glucokinase and GLUT-2 proteins increased after EMF treatment. According to the in vitro drug release test, 97% of all drug contained in fibers was released in a controlled manner for 24 h. The pharmacokinetic test revealed that the bioavailability was improved ∼4.8-fold with EMF treatment compared to EM-powder and blood glucose level was effectively controlled for 24 h with EMF. Oral administration of EMF exhibited a better sustainable anti-diabetic activity even in the half-dosage than EM-powder in streptozotocin/nicotinamide-induced T2DM rats. The levels of GLP-1, PPAR-γ, and insulin were increased while the levels of SGLT-2 and TNF-α were decreased with EMF treatment. Also, EMF recovered the histopathological changes in the liver, pancreas, and kidney in T2DM rats and protected pancreatic β-cells. Consequently, EMF is suggested as an unprecedented and promotive treatment approach for T2DM with a higher bioavailability and better antidiabetic effect compared to conventional dosage forms.
dc.identifier.citationGuler E., Nur Hazar-Yavuz A., TATAR E., Morid Haidari M., Sinemcan Ozcan G., DURUKSU G., Graça M. P. F., Kalaskar D. M., GÜNDÜZ O., Emin Cam M., "Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri-axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance", International Journal of Pharmaceutics, cilt.635, 2023
dc.identifier.doi10.1016/j.ijpharm.2023.122716
dc.identifier.issn0378-5173
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85148369075&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/287089
dc.identifier.volume635
dc.language.isoeng
dc.relation.ispartofInternational Journal of Pharmaceutics
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTROPİKAL TIP
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectTROPICAL MEDICINE
dc.subjectFarmasötik bilim
dc.subjectYaşam Bilimleri
dc.subjectPharmaceutical Science
dc.subjectLife Sciences
dc.subjectCore-sheath fiber
dc.subjectEmpagliflozin
dc.subjectInsulin resistance
dc.subjectTri-axial electrospinning
dc.subjectType 2 diabetes mellitus
dc.titleOral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri-axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance
dc.typearticle
dspace.entity.typePublication
local.avesis.id53166929-c8df-4ade-acec-ed03797dc6e4
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublicatione2c939bf-1387-4174-802c-e714419b20af
relation.isAuthorOfPublicationf11e8073-bf2f-485f-9bdf-5b3a2a0bdc1f
relation.isAuthorOfPublication.latestForDiscoverye2c939bf-1387-4174-802c-e714419b20af

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
8.pdf
Size:
11.87 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs